<DOC>
	<DOCNO>NCT00103181</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Giving radiation therapy different way may kill tumor cell remain surgery . It yet know whether whole breast radiation therapy effective partial breast radiation therapy treat breast cancer . PURPOSE : This randomized phase III trial study whole breast radiation therapy see well work compare partial breast radiation therapy treat woman undergone surgery ductal carcinoma situ stage I stage II breast cancer .</brief_summary>
	<brief_title>Radiation Therapy ( WBI Versus PBI ) Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ Stage I Stage II Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare local tumor control woman ductal carcinoma situ stage I II breast cancer treat adjuvant whole breast v partial breast irradiation follow lumpectomy . Secondary - Compare overall survival , recurrence-free survival , distant disease-free survival patient treat regimen . - Compare cosmetic result patient treat regimen . - Compare fatigue treatment-related symptom patient treat regimen . - Compare perceive convenience care patient treat regimen . - Compare acute late toxic effect regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify accord disease stage ( ductal carcinoma situ [ DCIS ] v invasive node negative vs invasive 1-3 positive node ) , menopausal status ( premenopausal v postmenopausal ) , hormone receptor status ( estrogen receptor [ ER ] -positive and/or progesterone receptor [ PR ] -positive v ER-negative PR-negative ) , intention receive chemotherapy ( yes v ) . Patients randomize 1 2 treatment arm . ( Patients 50 year age DCIS regardless hormone receptor status AND patient invasive breast cancer meeting follow criterion : ≥ 50 year age , node-negative , hormone-receptor positive status enrol study 12/30/2006 . ) - Group 1 : Patients undergo whole-breast irradiation ( WBI ) daily , 5 day week , 5-7 week . - Group 2 : Patients undergo partial-breast irradiation ( PBI ) twice daily 5 day period 5-10 day . This may deliver multi-catheter brachytherapy , single-entry intracavitary brachytherapy , 3-D conformal radiotherapy . Patients arm may receive adjuvant chemotherapy least 2 week prior initiation WBI OR least 2 week completion PBI discretion treat physician . Patients ER-positive PR-positive tumor may also receive hormonal therapy , begin 3-12 week completion adjuvant chemotherapy ( , , completion WBI PBI patient receive adjuvant chemotherapy ) continue least 5 year . After completion study treatment , patient follow 1 6 month , every 6 month 4.5 year , annually thereafter . PROJECTED ACCRUAL : A total 4,300 patient ( 2,150 per treatment arm ) accrue study within 4.6 year . Note : Accrual close April 16 , 2013 , follow approval Data Monitoring Committee reduce sample size 4,300 4,214 patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ductal carcinoma situ ( DCIS* ) invasive* adenocarcinoma breast Stage 0 , I , II disease Stage II tumor must ≤ 3 cm Gross disease must unifocal Microscopic multifocality allow provided total pathological tumor size ≤ 3 cm No proven multicentric carcinoma 1 quadrant separate ≥ 4 cm No nonepithelial breast malignancy ( e.g. , sarcoma lymphoma ) NOTE : *Patients 50 year age DCIS regardless hormone receptor status AND patient invasive breast cancer meeting follow criterion : ≥ 50 year age , nodenegative , hormonereceptor positive status enrol study 12/30/2006 Prior axillary staging require patient invasive breast cancer , include 1 following : Sentinel node biopsy alone ( sentinel node negative ) Sentinel node biopsy follow axillary dissection sample ≥ 6 axillary node ( sentinel node positive ) Axillary dissection alone ≥ 6 axillary node No 3 positive axillary node No axillary node definite evidence microscopic macroscopic extracapsular extension No positive nonaxillary sentinel node ( intramammary node stag axillary node ) No palpable radiographically suspicious ipsilateral contralateral axillary , supraclavicular , infraclavicular , internal mammary node unless histologic confirmation node negative tumor Must undergone lumpectomy Resected margin histologically free tumor Reexcision surgical margin allow Target lumpectomy cavity clearly delineate AND target lumpectomy/whole breast reference volume ≤ 30 % base postoperative prerandomization CT scan Final surgery ( i.e. , lumpectomy , reexcision margin , axillary staging procedure ) within past 42 day No suspicious microcalcifications , density , palpable abnormality ipsilateral contralateral breast unless biopsied find benign No Paget 's disease nipple No history invasive breast cancer DCIS Prior lobular carcinoma situ treat surgery alone allow No synchronous bilateral invasive noninvasive breast cancer Partial breast irradiation deem technically deliverable radiation oncologist credentialed facility Must undergone history physical exam within past 4 month AND bilateral mammogram within past 6 month Hormone receptor status : Estrogen receptor ( ER ) status know Progesterone status know ER analysis negative Marginal borderline result consider positive PATIENT CHARACTERISTICS : Age 18 Sex Female Menopausal status Premenopausal postmenopausal Performance status Not specify Life expectancy At least 10 year , exclude diagnosis breast cancer Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective nonhormonal contraception No malignancy within past 5 year except previously treat carcinoma situ cervix colon , melanoma situ , basal cell squamous cell skin cancer Deemed low risk recurrence No collagen vascular disease ( e.g. , systemic lupus erythematosus scleroderma ) , specifically dermatomyositis creatine phosphokinase ( CPK ) level normal , active skin rash No psychiatric addictive disorder would preclude study therapy PRIOR CONCURRENT THERAPY : Biologic therapy No prior biologic therapy malignancy Chemotherapy No prior chemotherapy malignancy No concurrent chemotherapy study radiotherapy Endocrine therapy No prior hormonal therapy malignancy unless total duration hormonal therapy 28 day randomization Concurrent hormonal therapy allow provide administer chemotherapy No concurrent raloxifene , tamoxifen , selective estrogen receptor modulate drug No concurrent hormone replacement therapy No concurrent Femring^® Radiotherapy No prior radiotherapy malignancy No prior breast thoracic radiotherapy No concurrent brachytherapy boost No concurrent intensity modulate radiotherapy No concurrent regional nodal irradiation Surgery See Disease Characteristics No prior breast implant Patients implant remove eligible Other No concurrent anticancer therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
	<keyword>breast cancer situ</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
</DOC>